Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30070640 | 1.00 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8981650 | 0.93 | CA2 (0.40) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Phosphoric Acid SCHEMBL4393635 | 0.91 | CA2 (0.42) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL16964715 | 0.88 | TSHR (0.39) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL29767007 | 0.86 | CA2 (0.41) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Propionic Acid SCHEMBL28970782 | 0.85 | CA2 (0.42) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Salicylic Acid SCHEMBL7597669 | 0.82 | ALDH1A1 (0.50) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Flavane SCHEMBL26661841 | 0.79 | ESR1 (0.54) | MAOBESR1ESR2 | |
| SCHEMBL19268290 | 0.78 | MAOA (0.45) | NISCHMAOAMAOB | |
| SCHEMBL458951 | 0.78 | MAOA (0.45) | NISCHMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109160911-A | A kind of preparation method of nebivolol | 雅本化学股份有限公司 | 2019-01-08 | — | — | CN | claimed |
| US-20180325164-A1 | LIQUID FORMULATION | JAYTEE BIOSCIENCES LIMITED (GB) | 2018-11-15 | — | — | US | claimed |
| EP-3373974-A1 | LIQUID FORMULATION | Jaytee Biosciences Limited (GB) | 2018-09-19 | — | — | EP | claimed |
| WO-2017081480-A1 | LIQUID FORMULATION | JAYTEE BIOSCIENCES LIMITED (GB) | 2017-05-18 | — | — | WO | claimed |
| EP-2308496-B1 | Formulation containing phosphate derivatives of electron transfer agents | VITAL HEALTH SCIENCES PTY LTD (AU) | 2015-04-15 | — | — | EP | claimed |
| EP-2531219-A1 | CARRIER COMPOSITION | Phosphagenics Limited (AU) | 2012-12-12 | — | — | EP | claimed |
| EP-2516011-A1 | CARRIER COMPOSITION | Phosphagenics Limited (AU) | 2012-10-31 | — | — | EP | claimed |
| US-20120202780-A1 | CARRIER COMPOSITION | PHOSPHAGENICS LIMITED (AU) | 2012-08-09 | — | — | US | claimed |
| EP-1339412-B1 | FORMULATION CONTAINING PHOSPHATE DERIVATIVES OF ELECTRON TRANSFER AGENTS | VITAL HEALTH SCIENCES PTY LTD (AU) | 2011-11-02 | — | — | EP | claimed |
| WO-2011094822-A1 | CARRIER COMPOSITION | PHOSPHAGENICS LIMITED (AU) | 2011-08-11 | — | — | WO | claimed |
| EP-1227104-A1 | PROCESSES FOR PRODUCING AND PURIFYING ASPARTAME DERIVATIVES AND PROCESS FOR PRODUCING PRODUCTION INTERMEDIATES | Ajinomoto Co., Inc. (JP) | 2002-07-31 | — | — | EP | claimed |
| EP-1163010-A1 | HEMOGLOBIN-ANTIOXIDANT CONJUGATES | HEMOSOL INC. (CA) | 2001-12-19 | — | — | EP | claimed |
| WO-2001094331-A2 | METHODS FOR PRODUCING AMINO-SUBSTITUTED CHROMANES | ELI LILLY & COMPANY (US) | 2001-12-13 | — | — | WO | claimed |
| WO-2001094330-A2 | METHODS FOR PRODUCING AMINO SUBSTITUTED CHROMANES | COR THERAPEUTICS, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| WO-2001087871-A2 | METHODS FOR PRODUCING AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-11-22 | — | — | WO | claimed |
| WO-2000056367-A1 | HEMOGLOBIN-ANTIOXIDANT CONJUGATES | HEMOSOL INC. (CA) | 2000-09-28 | — | — | WO | claimed |
| CN-1249306-A | Process for preparing benzodihydropyranol deriv. | BASF AG (DE) | 2000-04-05 | — | — | CN | claimed |
| CN-1218050-A | Sulfonamide-substituted benzopyran derivates processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-06-02 | — | — | CN | claimed |
| EP-0385584-B1 | Method for the preparation of 4-(cyclic-amido)-2H-1-benzopyrans and 4-amino-3-hydroxy-2H-1-benzopyrans | BEECHAM GROUP PLC (GB) | 1995-05-24 | — | — | EP | claimed |
| US-5126460-A | PROCESS FOR PREPARING BENZOYPYRANOL DERIVATIVES | BEECHAM GROUP P.L.C. (GB) | 1992-06-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202780-A1 | CARRIER COMPOSITION | SLC35B2, SLC34A2, SLC20A2 | CA2 1221/4885HTR1A 3306/4885SIGMAR1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.